Natural product MDM2 inhibitors: anticancer activity and mechanisms of action.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current Medicinal Chemistry

• Publication date

  2012-10-31

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/092986712803988910PMID 22830335PMCID PMC6690201
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ribosomal protein S14 unties the MDM2–p53 loop upon ribosomal stress

  2013cited by this paper
• Identification of ribosomal protein S25 (RPS25)–MDM2–p53 regulatory feedback loop

  2013cited by this paper
• Hoiamide D, a marine cyanobacteria-derived inhibitor of p53/MDM2 interaction.

  2012cited by this paper
• Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure–Activity Relationships, and Molecular Mechanisms of Action

  2012cited by this paper
• p53–Mdm2 inhibitors: patent review (2009 – 2010)

  2012influential reference
• MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells

  2011cited by this paper
• The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo

  2011cited by this paper
• Experimental Therapy of Ovarian Cancer with Synthetic Makaluvamine Analog: In Vitro and In Vivo Anticancer Activity and Molecular Mechanisms of Action

  2011influential reference
• MDM2 is Overexpressed and Regulated by the Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Squamous Cell Carcinoma of Esophagus

  2011cited by this paper
• Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.

  2011cited by this paper
• [Drug discovery and natural products: end of era or an endless frontier?].

  2011cited by this paper
• Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.

  2011cited by this paper
• RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis

  2011cited by this paper
• MDM2 Regulates Vascular Endothelial Growth Factor mRNA Stabilization in Hypoxia

  2011cited by this paper
• Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop.

  2011cited by this paper
• A novel oncoprotein Pirh2: rising from the shadow of MDM2

  2011cited by this paper
• Alternative strategies for targeting mouse double minute 2 activity with small molecules: novel patents on the horizon?

  2011cited by this paper
• TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.

  2010cited by this paper
• p53 at a glance

  2010cited by this paper
• MDM2 Promotes Proteasomal Degradation of p21Waf1 via a Conformation Change*

  2010cited by this paper
• Nucleostemin

  2010cited by this paper
• Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.

  2010cited by this paper
• The multiple levels of regulation by p53 ubiquitination

  2010cited by this paper
• NF-κB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2

  2010cited by this paper
• A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action

  2010cited by this paper
• Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway

  2010cited by this paper
• Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73

  2010cited by this paper
• Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications.

  2010cited by this paper
• Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells.

  2010influential reference
• MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity

  2010cited by this paper
• Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.

  2010influential reference
• Translating p53 into the clinic

  2010cited by this paper
• Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1

  2010cited by this paper
• Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53

  2010cited by this paper
• S100 proteins interact with the N‐terminal domain of MDM2

  2010cited by this paper
• The C-terminus of p53 binds the N-terminal domain of MDM2

  2010influential reference
• The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.

  2010cited by this paper
• Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action.

  2009cited by this paper
• Involvement of p53 in oroxylin A‐induced apoptosis in cancer cells

  2009cited by this paper
• Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.

  2009cited by this paper
• Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions

  2009cited by this paper
• Recent advances in validating MDM2 as a cancer target.

  2009cited by this paper
• GA3, a new gambogic acid derivative, exhibits potent antitumor activities in vitro via apoptosis-involved mechanisms

  2009influential reference
• In vitro and In vivo Anticancer Activity of Novel Synthetic Makaluvamine Analogues

  2009cited by this paper
• Signaling to p53: ribosomal proteins find their way.

  2009cited by this paper
• Synthesis of the Chlorofusin Cyclic Peptide.

  2009cited by this paper
• Stereochemical studies of hexylitaconic acid, an inhibitor of p53-HDM2 interaction.

  2009cited by this paper
• p53 and MDM2: antagonists or partners in crime?

  2009cited by this paper
• Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.

  2009cited by this paper
• RING domain E3 ubiquitin ligases.

  2009influential reference
• Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors.

  2009cited by this paper
• Synthesis and in vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs.

  2009cited by this paper
• Evaluation of Chlorofusin, its Seven Chromophore Diastereomers, and Key Analogues.

  2009cited by this paper
• Awakening guardian angels: drugging the p53 pathway

  2009cited by this paper
• Drug Discovery and Natural Products: End of an Era or an Endless Frontier?

  2009cited by this paper
• Mdm2 affects genome stability independent of p53.

  2009cited by this paper
• Cytotoxic diarylheptanoid induces cell cycle arrest and apoptosis via increasing ATF3 and stabilizing p53 in SH-SY5Y cells

  2009cited by this paper
• Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD.

  2009cited by this paper
• Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.

  2009cited by this paper
• MDM2 Acts Downstream of p53 as an E3 Ligase to Promote FOXO Ubiquitination and Degradation*

  2009cited by this paper
• Ribosomal protein S7 is both a regulator and a substrate of MDM2.

  2009influential reference
• The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interaction.

  2009cited by this paper
• Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53.

  2009cited by this paper
• Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2

  2009cited by this paper
• Regulation of XIAP translation and induction by MDM2 following irradiation.

  2009cited by this paper
• Identification of Inhibitors for MDM2 Ubiquitin Ligase Activity from Natural Product Extracts by a Novel High-Throughput Electrochemiluminescent Screen

  2008cited by this paper
• Oncogenes and cancer.

  2008cited by this paper
• Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53.

  2008cited by this paper
• Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action

  2008cited by this paper
• Antileukemic activity of aminoparthenolide analogs.

  2008cited by this paper
• Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity.

  2008cited by this paper
• Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells

  2008cited by this paper
• TAp73α Increases p53 Tumor Suppressor Activity in Thyroid Cancer Cells via the Inhibition of Mdm2-Mediated Degradation

  2008cited by this paper
• Experimental therapy of prostate cancer with novel natural product anti‐cancer ginsenosides

  2008cited by this paper
• Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

  2008cited by this paper
• Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation

  2008influential reference
• Small molecule inhibitors of the p53-MDM2.

  2008cited by this paper
• Diagnosing and exploiting cancer's addiction to blocks in apoptosis

  2008cited by this paper
• Regulation of angiogenic factors by HDM2 in renal cell carcinoma.

  2008cited by this paper
• Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties

  2008cited by this paper
• Effect of pure curcumin, demethoxycurcumin, and bisdemethoxycurcumin on WT1 gene expression in leukemic cell lines

  2008cited by this paper
• Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.

  2008cited by this paper
• 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action

  2008cited by this paper
• ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

  2008cited by this paper
• Inhibition of the Human Double Minute (HDM)-2 E3 Ubiquitin Ligase Activates Different Programmed Cell Death (PCD) Pathways in Models of Non-Hodgkin Lymphoma (NHL) with Wild Type (wt) and Mutant (mut) p53

  2008cited by this paper
• Synthesis and antiproliferative activity of benzyl and phenethyl analogs of makaluvamines.

  2008cited by this paper
• Total synthesis of chlorofusin, its seven chromophore diastereomers, and key partial structures.

  2008cited by this paper
• Concerted activation of the Mdm2 promoter by p72 RNA helicase and the coactivators p300 and P/CAF

  2007cited by this paper
• Ribosomal protein S7 as a novel modulator of p53–MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function

  2007cited by this paper
• Solid-phase synthesis of chlorofusin analogues.

  2007cited by this paper
• MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis.

  2007cited by this paper
• MDM2 inhibitors for cancer therapy.

  2007cited by this paper
• Total Synthesis, Stereochemical Reassignment, and Absolute Configuration of Chlorofusin

  2007cited by this paper
• In Cultured Astrocytes, p53 and MDM2 Do Not Alter Hypoxia-inducible Factor-1α Function Regardless of the Presence of DNA Damage*

  2007cited by this paper
• Synthesis and Cytotoxic Evaluation of Novel 7‐O‐Modified Genistein Derivatives

  2007cited by this paper
• Caspase-8 preferentially senses the apoptosis-inducing action of NG-18, A gambogic acid derivative, in human leukemia HL-60 cells

  2007cited by this paper
• Natural products as sources of new drugs over the last 25 years.

  2007cited by this paper
• Isolation, structural determination, and evaluation of the biological activity of 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol [20(S)-25-OCH3-PPD], a novel natural product from Panax notoginseng.

  2007cited by this paper
• Mdm2 targets the p53 transcription cofactor JMY for degradation

  2007cited by this paper
• In vitro anti-cancer activity and structure–activity relationships of natural products isolated from fruits of Panax ginseng

  2007cited by this paper

• Mechanism of berbamine-mediated DNA damage in synovial fibroblasts to alleviate rheumatoid arthritis.

  2025cites this paper
• Inhibition of MDM2 by nutlin-3 decreased pyroptosis but increased apoptosis of lung carcinoma cells under 5-FU chemotherapy.

  2025cites this paper
• Anti-cancer activity elucidation of geissolosimine as an MDM2-p53 interaction inhibitor: An in-silico study

  2025cites this paper
• CopA3 peptide inhibits MDM2-p53 complex stability in colorectal cancers and activates p53 mediated cell death machinery.

  2023cites this paper
• Remodeling tumor microenvironment with natural products to overcome drug resistance

  2022cites this paper
• Japonicone A and related dimeric sesquiterpene lactones: molecular targets and mechanisms of anticancer activity

  2022cites this paper
• In-silico and in-vitro evaluation of docetaxel and berberine as potential p53 modulating apoptotic inducers in oral squamous cell carcinoma

  2022cites this paper
• A MDM2 inhibitor MX69 inhibits adipocytes adipogenesis and differentiation.

  2022cites this paper
• The role of miRNAs in MDMX‐p53 interplay

  2021cites this paper
• Regulation of p53 by E3s

  2021cites this paper
• The roles and regulation of MDM2 and MDMX: it is not just about p53

  2021cites this paper
• An insight into cytotoxic activity of flavonoids and sesquiterpenoids from selected plants of Asteraceae species

  2021cites this paper
• Asymmetric organocatalysis: an enabling technology for medicinal chemistry.

  2021cites this paper
• Targeting MDM2 for novel molecular therapy: Beyond oncology

  2020cites this paper
• Apoptosis Induced by Melatonin and Vitamin D3 in MCF-7 Breast Cancer Cell Line by Upregulating the Gene Expression of P53

  2020cites this paper
• Par-4 activation restrains EMT-induced chemoresistance in PDAC by attenuating MDM-2.

  2020cites this paper
• Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.

  2020cites this paper
• A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer.

  2020cites this paper
• Semi-comprehensive analysis of gene amplification in thymic malignant tumors using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.

  2020cites this paper
• Anticancer strategies by upregulating p53 through inhibition of its ubiquitination by MDM2

  2020cites this paper
• In vitro and computational studies showed that perezone inhibits PARP-1 and induces changes in the redox state of K562 cells.

  2019cites this paper
• Using recursive partitioning approach to select tumor‐associated antigens in immunodiagnosis of gastric adenocarcinoma

  2019cites this paper
• Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine

  2018cites this paper
• Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy

  2018cites this paper
• Exploring the Cytotoxic Potential of Triterpenoids-enriched Fraction of Bacopa monnieri by Implementing In vitro, In vivo, and In silico Approaches

  2017cites this paper
• Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53–MDM2 Interaction Useful in Targeted Cancer Therapy

  2017cites this paper
• Novel natural product therapeutics targeting both inflammation and cancer.

  2017cites this paper
• Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway.

  2017cites this paper
• Sanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway

  2016cites this paper
• Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy

  2016cites this paper
• Autoantibodies against tumor-associated antigens in the early detection of lung cancer.

  2016cites this paper
• Discovery and development of synthetic tricyclic pyrroloquinone (TPQ) alkaloid analogs for human cancer therapy

  2016cites this paper
• Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.

  2016cites this paper
• Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA

  2015cites this paper
• Novel structurally similar chromene derivatives with opposing effects on p53 and apoptosis mechanisms in colorectal HCT116 cancer cells.

  2015cites this paper
• Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice.

  2015cites this paper
• Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action

  2015cites this paper
• Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats.

  2015cites this paper
• Targeting MDM2-p53 interaction for cancer therapy: are we there yet?

  2014cites this paper
• Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation

  2014cites this paper
• MDM2 SNP309 variation increases cervical cancer risk among Asians

  2014cites this paper
• Targeting p53-MDM2-MDMX loop for cancer therapy.

  2014cites this paper
• Nutraceuticals in Preventive Oncology: Chemical Biology and Translational Pharmaceutical Science

  2014cites this paper
• Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.

  2014cites this paper
• Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma.

  2014cites this paper
• Effect of Galium verum aqueous extract on growth, motility and gene expression in drug-sensitive and -resistant laryngeal carcinoma cell lines.

  2014cites this paper
• The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models

  2014cites this paper
• A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study.

  2014cites this paper
• Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.

  2013cites this paper
• The MDM2-p53 pathway revisited

  2013cites this paper
• HOXB1 restored expression promotes apoptosis and differentiation in the HL60 leukemic cell line

  2013cites this paper
• The MDM 2p 53 pathway revisited

  2013cites this paper
• Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agents.

  2013cites this paper
• Newcastle University E-prints Citation for Item: P53, Skp2, and Dkk3 as Mycn Target Genes and Their Potential Therapeutic Significance

  year unknowncites this paper